Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Cohort Study · 2014 · 436 citations
2Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerCohort Study · 2015 · 2,975 citations
3Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocolsRCT · 2017 · 89 citations
4Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyRandomized Controlled Trial · 2017 · 1,844 citations
5Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialRandomized Controlled Trial · 2015 · 2,041 citations
6Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)Cohort Study · 2022 · 83 citations
7Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trialRCT · 2019 · 873 citations
8Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyRCT · 2021 · 544 citations
9Zamtocabtagene autoleucel, a tandem CD20–CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 studyThe Lancet Oncology · 2026
10Global burden of cancer attributable to infections in 2024: a worldwide incidence analysisThe Lancet Oncology · 2026

More from The Lancet Oncology

More from University College London